By Chris Wack

 

Annovis Bio Inc. shares were up 6% to $14.18 early Thursday after the drug-platform company said the U.S. Food and Drug Administration authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease.

Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the company requested approval to further pursue the development of buntanetap in AD.

The FDA approved the company's development plan, study protocol and authorized the initiation of the Phase 2/3 clinical study of buntanetap in AD.

Annovis stock is up 40% in the last month.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

October 06, 2022 10:19 ET (14:19 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more Annovis Bio Charts.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more Annovis Bio Charts.